Carl Heneghan in action

CEBM Workshops Video Sample - Carl Heneghan - Diagnostic Tests See Carl Heneghan in action in the CEBM's workshop videos. Click here

Tags

HONcode Certified

This website is certified by Health On the Net Foundation. Click to verify.

This site complies with the HONcode standard for trustworthy health information: verify here.

Yet more evidence against aspirin in primary prevention

Ami Banerjee
Last edited 17th March 2010

At the European Society for Cardiology Congress this week, we learned about more situations where aspirin is unhelpful. Professor Gerry Fowkes and colleagues from Edinburgh looked at nearly 30000 men and women aged 50 to 80 years who had never had any cardiovascular disease, but had a low ankle-brachial pressure index, a marker of peripheral vascular disease. The ankle brachial index (ABI) is the ratio of the blood pressure in the arm to the blood pressure at the ankle, and is an indicator of subclinical atherosclerosis. The ABI predicts risk of major vascular events in healthy populations, independently of established cardiovascular risk factors, such as diabetes, smoking and cholesterol. The Edinburgh team recruited over 3000 people with low ABI from their population and randomised them to 100mg aspirin or placebo, with 8 years of follow-up.

There was no difference between aspirin and placebo whether we look at cardiovascular events or all cause mortality, and there were more major bleeds in the aspirin arm of the trial. Same bottom line as before: do not give aspirin to people before they have a vascular event.

The time delay to policy

The Royal College of GPs and the Drug and Therapeutics Bulletin have agreed that aspirin should not be used in people who do not have not had heart disease or strokes. It shows the time lag between evidence and its implementation at policy level...

http://news.bbc.co.uk/1/hi/health/8338763.stm

Twitter TrustTheEvidence.net

tte
     

Search the TRIP Database

TRIP Database

 

Recent Comments